Search

Perry, J. A., A. Kiezun, P. Tonzi, E. M. Van Allen, S. L. Carter, S. C. Baca, G. S. Cowley, et al. 2014. “Complementary Genomic Approaches Highlight the PI3K/MTOR Pathway As a Common Vulnerability in Osteosarcoma”. Proc Natl Acad Sci U S A 111: E5564-73.

Savage, K. J., S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. Leval, P. Kurtin, et al. 2003. “The Molecular Signature of Mediastinal Large B-Cell Lymphoma Differs from That of Other Diffuse Large B-Cell Lymphomas and Shares Features With Classical Hodgkin Lymphoma”. Blood 102: 3871-9.

Sboner, A., F. Demichelis, S. Calza, Y. Pawitan, S. R. Setlur, Y. Hoshida, S. Perner, et al. 2010. “Molecular Sampling of Prostate Cancer: A Dilemma for Predicting Disease Progression”. BMC Med Genomics 3: 8.

Setlur, S. R., K. D. Mertz, Y. Hoshida, F. Demichelis, M. Lupien, S. Perner, A. Sboner, et al. 2008. “Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer”. J Natl Cancer Inst 100: 815-25.

Solit, D. B., L. A. Garraway, C. A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, et al. 2006. “BRAF Mutation Predicts Sensitivity to MEK Inhibition”. Nature 439: 358-62.

Stathias, V., A. M. Jermakowicz, M. E. Maloof, M. Forlin, W. Walters, R. K. Suter, M. A. Durante, et al. 2018. “Drug and Disease Signature Integration Identifies Synergistic Combinations in Glioblastoma”. Nat Commun 9: 5315.

Staunton, J. E., D. K. Slonim, H. A. Coller, P. Tamayo, M. J. Angelo, J. Park, U. Scherf, et al. 2001. “Chemosensitivity Prediction by Transcriptional Profiling”. Proc Natl Acad Sci U S A 98: 10787-92.

Stegmaier, K., J. S. Wong, K. N. Ross, K. T. Chow, D. Peck, R. D. Wright, S. L. Lessnick, A. L. Kung, and T. R. Golub. 2007. “Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside As an EWS/FLI Modulator in Ewing Sarcoma”. PLoS Med 4: e122.

Straussman, R., T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, et al. 2012. “Tumour Micro-Environment Elicits Innate Resistance to RAF Inhibitors through HGF Secretion”. Nature 487: 500-4.

Takeuchi, S., T. Seriu, C. R. Bartram, T. R. Golub, A. Reiter, I. Miyoshi, D. G. Gilliland, and H. P. Koeffler. 1997. “TEL Is One of the Targets for Deletion on 12p in Many Cases of Childhood B-Lineage Acute Lymphoblastic Leukemia”. Leukemia 11: 1220-3.